Drugs.com - New Drug Approvals

ARS Pharmaceuticals Announces FDA Approval of neffy 1 mg (epinephrine nasal spray) for Type I Allergic Reactions in Pediatric Patients

SAN DIEGO, March 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to...

Mar 6, 2025 - 04:03
 0
ARS Pharmaceuticals Announces FDA Approval of neffy 1 mg (epinephrine nasal spray) for Type I Allergic Reactions in Pediatric Patients
SAN DIEGO, March 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to...
Read More

Tags:

Previous Article

Opinion: A Trump Tweet Can Cripple Markets, Ignite Wars and Reshape History

Next Article

Recurrent contracts GRS to build 171MW solar PV plant in Victoria, Australia

Related Posts

FDA Approves Penmenvy (meningococcal groups A, B, C, W, and Y vaccine) for Prevention of Invasive Meningococcal Disease Caused by Serogroups A, B, C, W, and Y

FDA Approves Penmenvy (meningococcal groups A, B, C, W,...

Feb 17, 2025  0

FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)

FDA Approves Genentech’s Evrysdi Tablet as First and On...

Feb 13, 2025  0

FDA Approves Lilly's Omvoh (mirikizumab-mrkz) for Crohn's Disease, Expanding Its Use to the Second Major Type of Inflammatory Bowel Disease

FDA Approves Lilly's Omvoh (mirikizumab-mrkz) for Crohn...

Feb 9, 2025  0